Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous TROP2-CAR-transduced PD-1-positive T cells T60c

A preparation of autologous programmed cell death protein 1 (PD-1; PDCD1; CD279)-positive T lymphocytes transduced with a lentivirus expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; tumor-associated calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), with potential immunostimulating and antineoplastic activities. Upon administration, autologous TROP2-CAR-transduced PD-1-positive T cells T60c target, bind to and induce selective cytotoxicity in TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:TROP2-CAR-transduced PD-1-positive T cells T60c
Code name:T 60c
T-60c
T60c
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search